A phase I clinical study of NV-103 in Ewing's sarcoma
Latest Information Update: 06 Aug 2020
At a glance
- Drugs NV 103 (Primary)
- Indications Ewing's sarcoma
- Focus Adverse reactions
- Sponsors NanoValent Pharmaceuticals
Most Recent Events
- 06 Aug 2020 New trial record